SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following is a summary of awards outstanding as of December 31, 2025 and 2024, which are not included in the computation of basic and diluted weighted average shares:


	Year ended December 31,
	2025		2024
Stock options (excluding exercisable penny stock options)		9,005,780		7,232,926
Restricted		457,522		283,411
Warrants		5,827,035		5,152,397
Total		15,290,337		12,668,734

Schedule of Significant Segment Expenses

In addition to the significant expense categories included within the total net loss presented on the Company's Statements of Operations, the following table sets forth significant segment expenses:


	Year ended December 31,
(in thousands)	2025		2024
Employee expenses	$	11,705	$	9,971
Research and Development (excluding employee expenses):
Consulting and professional fees		1,564		2,845
Clinical study expenses		364		1,038
Product development		2,983		1,594
Other*		1,392		982
Total Research and development expense	$	6,303	$	6,459
General and administrative expense (excluding employee expenses):
General and administrative expenses		2,224		2,824
Commercialization readiness expenses		907		633
Total General and administrative expense		3,131		3,457
Total operating expenses	$	21,139	$	19,887

* Other primarily includes patent fees and testing expenses for years ended December 31, 2025 and 2024.

HeartBeam, Inc. 10-K